Search

Your search keyword '"Loré, Karin"' showing total 6 results
Start Over Author "Loré, Karin" Journal immunity
6 results on '"Loré, Karin"'

1. Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination

Author

Gao, Yu, Cai, Curtis, Wullimann, David, Niessl, Julia, Rivera-Ballesteros, Olga, Chen, Puran, Lange, Joshua, Cuapio, Angelica, Blennow, Ola, Hansson, Lotta, Mielke, Stephan, Nowak, Piotr, Vesterbacka, Jan, Akber, Mira, Perez-Potti, Andre, Sekine, Takuya, Müller, Thomas R., Boulouis, Caroline, Kammann, Tobias, Parrot, Tiphaine, Muvva, Jagadeeswara Rao, Sobkowiak, Michal, Healy, Katie, Bogdanovic, Gordana, Muschiol, Sandra, Söderdahl, Gunnar, Österborg, Anders, Hellgren, Fredrika, Grifoni, Alba, Weiskopf, Daniela, Sette, Alessandro, Loré, Karin, Sällberg Chen, Margaret, Ljungman, Per, Sandberg, Johan K., Smith, C.I. Edvard, Bergman, Peter, Ljunggren, Hans-Gustaf, Aleman, Soo, and Buggert, Marcus

Published
2022
Full Text
View/download PDF

2. Limited access to antigen drives generation of early B cell memory while restraining the plasmablast response

Author

Glaros, Vassilis, Rauschmeier, René, Artemov, Artem V., Reinhardt, Annika, Ols, Sebastian, Emmanouilidi, Aikaterini, Gustafsson, Charlotte, You, Yuanyuan, Mirabello, Claudio, Björklund, Åsa K., Perez, Laurent, King, Neil P., Månsson, Robert, Angeletti, Davide, Loré, Karin, Adameyko, Igor, Busslinger, Meinrad, and Kreslavsky, Taras

Published
2021
Full Text
View/download PDF

3. Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach

Author

Martinez-Murillo, Paola, Tran, Karen, Guenaga, Javier, Lindgren, Gustaf, Àdori, Monika, Feng, Yu, Phad, Ganesh E., Vázquez Bernat, Néstor, Bale, Shridhar, Ingale, Jidnyasa, Dubrovskaya, Viktoriya, O’Dell, Sijy, Pramanik, Lotta, Spångberg, Mats, Corcoran, Martin, Loré, Karin, Mascola, John R., Wyatt, Richard T., and Karlsson Hedestam, Gunilla B.

Published
2017
Full Text
View/download PDF

6. Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses.

Author

Ols S, Lenart K, Arcoverde Cerveira R, Miranda MC, Brunette N, Kochmann J, Corcoran M, Skotheim R, Philomin A, Cagigi A, Fiala B, Wrenn S, Marcandalli J, Hellgren F, Thompson EA, Lin A, Gegenfurtner F, Kumar A, Chen M, Phad GE, Graham BS, Perez L, Borst AJ, Karlsson Hedestam GB, Ruckwardt TJ, King NP, and Loré K

Abstract

Nanoparticles for multivalent display and delivery of vaccine antigens have emerged as a promising avenue for enhancing B cell responses to protein subunit vaccines. Here, we evaluated B cell responses in rhesus macaques immunized with prefusion-stabilized respiratory syncytial virus (RSV) F glycoprotein trimer compared with nanoparticles displaying 10 or 20 copies of the same antigen. We show that multivalent display skews antibody specificities and drives epitope-focusing of responding B cells. Antibody cloning and repertoire sequencing revealed that focusing was driven by the expansion of clonally distinct B cells through recruitment of diverse precursors. We identified two antibody lineages that developed either ultrapotent neutralization or pneumovirus cross-neutralization from precursor B cells with low initial affinity for the RSV-F immunogen. This suggests that increased avidity by multivalent display facilitates the activation and recruitment of these cells. Diversification of the B cell response by multivalent nanoparticle immunogens has broad implications for vaccine design., Competing Interests: Declaration of interests N.P.K., B.F., L.P., and J.M. are named as inventors on patent applications filed by the University of Washington related to the data presented in this work. N.P.K. is a co-founder and shareholder in Icosavax, a company that has licensed the patent applications, and is a member of Icosavax’s Scientific Advisory Board. The King lab has received unrelated sponsored research agreements from Pfizer and GSK. B.S.G. is an inventor on patents for the stabilization of the RSV-F protein (WO2014160463A1, preF RSV-F proteins and their use)., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results